Cellumed Co. Ltd
Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFß-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi… Read more
Cellumed Co. Ltd (049180) - Net Assets
Latest net assets as of September 2025: ₩16.52 Billion KRW
Based on the latest financial reports, Cellumed Co. Ltd (049180) has net assets worth ₩16.52 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩71.62 Billion) and total liabilities (₩55.10 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩16.52 Billion |
| % of Total Assets | 23.07% |
| Annual Growth Rate | -10.11% |
| 5-Year Change | -68.77% |
| 10-Year Change | -78.73% |
| Growth Volatility | 123.72 |
Cellumed Co. Ltd - Net Assets Trend (2008–2024)
This chart illustrates how Cellumed Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cellumed Co. Ltd (2008–2024)
The table below shows the annual net assets of Cellumed Co. Ltd from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩8.78 Billion | -61.87% |
| 2023-12-31 | ₩23.02 Billion | -57.33% |
| 2022-12-31 | ₩53.94 Billion | +12.41% |
| 2021-12-31 | ₩47.99 Billion | +70.77% |
| 2020-12-31 | ₩28.10 Billion | +442.35% |
| 2019-12-31 | ₩5.18 Billion | -77.49% |
| 2018-12-31 | ₩23.02 Billion | -38.27% |
| 2017-12-31 | ₩37.28 Billion | -19.93% |
| 2016-12-31 | ₩46.56 Billion | +12.83% |
| 2015-12-31 | ₩41.27 Billion | -6.23% |
| 2014-12-31 | ₩44.01 Billion | -10.55% |
| 2013-12-31 | ₩49.20 Billion | +0.93% |
| 2012-12-31 | ₩48.75 Billion | +53.52% |
| 2011-12-31 | ₩31.75 Billion | -34.25% |
| 2008-12-31 | ₩48.29 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cellumed Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14112936968000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩25.76 Billion | 293.49% |
| Other Components | ₩124.15 Billion | 1414.54% |
| Total Equity | ₩8.78 Billion | 100.00% |
Cellumed Co. Ltd Competitors by Market Cap
The table below lists competitors of Cellumed Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ALLERGY THER. PLC LS-001
F:HHU
|
$32.46 Million |
|
Ouro Fino Saúde Animal Participações S.A
SA:OFSA3
|
$32.46 Million |
|
Mutual-Tek Industries Co., Ltd.
TWO:6407
|
$32.46 Million |
|
Shangri La Hotels Malaysia Bhd
KLSE:5517
|
$32.47 Million |
|
Romerike Sparebank
OL:ROMER
|
$32.44 Million |
|
Careium AB
ST:CARE
|
$32.44 Million |
|
District Metals Corp.
PINK:DMXCF
|
$32.43 Million |
|
Marathon Bancorp, Inc. Common Stock
PINK:MBBC
|
$32.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cellumed Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 22,461,292,290 to 8,776,537,130, a change of -13,684,755,160 (-60.9%).
- Net loss of 31,545,183,300 reduced equity.
- Share repurchases of 12,000,001,760 reduced equity.
- New share issuances of 12,000,001,750 increased equity.
- Other factors increased equity by 17,860,428,150.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-31.55 Billion | -359.43% |
| Share Repurchases | ₩12.00 Billion | -136.73% |
| Share Issuances | ₩12.00 Billion | +136.73% |
| Other Changes | ₩17.86 Billion | +203.5% |
| Total Change | ₩- | -60.93% |
Book Value vs Market Value Analysis
This analysis compares Cellumed Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.92x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.39x to 5.92x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩2564.77 | ₩1009.00 | x |
| 2017-12-31 | ₩1980.59 | ₩1009.00 | x |
| 2018-12-31 | ₩1292.38 | ₩1009.00 | x |
| 2019-12-31 | ₩212.99 | ₩1009.00 | x |
| 2020-12-31 | ₩814.22 | ₩1009.00 | x |
| 2021-12-31 | ₩1211.88 | ₩1009.00 | x |
| 2022-12-31 | ₩1291.55 | ₩1009.00 | x |
| 2023-12-31 | ₩524.85 | ₩1009.00 | x |
| 2024-12-31 | ₩170.40 | ₩1009.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cellumed Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -359.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -24.43%
- • Asset Turnover: 1.84x
- • Equity Multiplier: 8.00x
- Recent ROE (-359.43%) is below the historical average (-119.20%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.33% | 0.52% | 0.37x | 1.69x | ₩-4.74 Billion |
| 2014 | -33.25% | -71.92% | 0.29x | 1.57x | ₩-19.40 Billion |
| 2015 | -26.61% | -63.99% | 0.22x | 1.92x | ₩-15.61 Billion |
| 2016 | -79.14% | -375.49% | 0.14x | 1.50x | ₩-41.51 Billion |
| 2017 | -19.07% | -37.41% | 0.29x | 1.74x | ₩-10.84 Billion |
| 2018 | -35.12% | -85.48% | 0.22x | 1.88x | ₩-11.91 Billion |
| 2019 | -719.12% | -207.90% | 0.28x | 12.54x | ₩-37.78 Billion |
| 2020 | 0.30% | 0.09% | 1.29x | 2.52x | ₩-2.72 Billion |
| 2021 | 17.05% | 8.19% | 1.04x | 2.01x | ₩3.38 Billion |
| 2022 | -10.33% | -4.56% | 1.31x | 1.73x | ₩-10.97 Billion |
| 2023 | -166.05% | -39.03% | 1.44x | 2.96x | ₩-39.54 Billion |
| 2024 | -359.43% | -24.43% | 1.84x | 8.00x | ₩-32.42 Billion |
Industry Comparison
This section compares Cellumed Co. Ltd's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $388,616,360,019
- Average return on equity (ROE) among peers: 7.74%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cellumed Co. Ltd (049180) | ₩16.52 Billion | 0.33% | 3.34x | $32.46 Million |
| DIO Corporation (039840) | $194.43 Billion | 1.70% | 0.89x | $94.83 Million |
| SD Biosensor Inc (137310) | $2.20 Trillion | 48.32% | 0.36x | $174.83 Million |
| Dentium (145720) | $291.10 Billion | 19.06% | 0.96x | $192.13 Million |
| M.I.TECH Co.Ltd (179290) | $14.71 Billion | 4.08% | 0.17x | $45.98 Million |
| JETEMA Co. Ltd (216080) | $-5.04 Billion | 0.00% | 0.00x | $148.99 Million |
| Biodyne Co. Ltd. (314930) | $6.58 Billion | -30.82% | 2.54x | $144.24 Million |
| HASS Corp (450330) | $15.15 Billion | 11.85% | 0.93x | $11.51 Million |